Zobrazeno 1 - 10
of 402
pro vyhledávání: '"Tjalling, Bosse"'
Autor:
Anneke L. Eerkens, Koen Brummel, Annegé Vledder, Sterre T. Paijens, Marta Requesens, Dominik Loiero, Nienke van Rooij, Annechien Plat, Floris-Jan Haan, Patty Klok, Refika Yigit, Thijs Roelofsen, Natascha M. de Lange, Rie Klomp, David Church, Arja ter Elst, René Wardenaar, Diana Spierings, Floris Foijer, Viktor Hendrik Koelzer, Tjalling Bosse, Joost Bart, Mathilde Jalving, Anna K. L. Reyners, Marco de Bruyn, Hans W. Nijman
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Neoadjuvant immune checkpoint blockade (ICB) has shown unprecedented activity in mismatch repair deficient (MMRd) colorectal cancers, but its effectiveness in MMRd endometrial cancer (EC) remains unknown. In this investigator-driven, phase I
Externí odkaz:
https://doaj.org/article/1b7aedf643dd44ed914769ada0de8d61
Autor:
Gareth Evans, Tjalling Bosse, David N Church, Noel de Miranda, James Bolton, Neil Ryan, Emma Crosbie, Thomas Walker, Marieke Ijsselsteijn, Mark Glaire, Natalja ter Haar
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective To explore the impact of molecular subtype in endometrial cancer (EC) on CD8+T cell densities. Furthermore, this work will test the assumption that all mismatch repair deficient (MMRd) tumours are immunologically similar which would enable
Externí odkaz:
https://doaj.org/article/0d7d9326c85c4ec0a50f47499e3953a4
Autor:
Claire JH Kramer, Alba Llop‐Guevara, Elisa Yaniz‐Galende, Benedetta Pellegrino, Natalja T terHaar, Andrea Herencia‐Ropero, Nicoletta Campanini, Antonino Musolino, Tjalling Bosse, Alexandra Leary, Violeta Serra, Maaike PG Vreeswijk
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 9, Iss 6, Pp 442-448 (2023)
Abstract The RAD51 test is emerging as a promising biomarker for the assessment of functional homologous recombination deficiency (HRD). Yet, the robustness and reproducibility of the immunofluorescence‐based RAD51 test, in different academic labor
Externí odkaz:
https://doaj.org/article/fba349eabeb84ca8af5db56235c061a6
Autor:
Matthew Brown, Alicia Leon, Katarzyna Kedzierska, Charlotte Moore, Hayley L Belnoue‐Davis, Susanne Flach, John P Lydon, Francesco J DeMayo, Annabelle Lewis, Tjalling Bosse, Ian Tomlinson, David N Church
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 10, Pp n/a-n/a (2023)
Abstract High‐risk endometrial cancer has poor prognosis and is increasing in incidence. However, understanding of the molecular mechanisms which drive this disease is limited. We used genetically engineered mouse models (GEMM) to determine the fun
Externí odkaz:
https://doaj.org/article/5c8f6de2c4ae45eeb10187d03d135ae1
Autor:
Anne Sophie V.M. Van den Heerik, Natalja T. Ter Haar, Lisa Vermij, Jan J. Jobsen, Mariel Brinkhuis, Suzan M. Roothaan, Alicia Leon-Castillo, Gitte Ortoft, Estrid Hogdall, Claus Hogdall, Tom Van Wezel, Ludy C.H.W. Lutgens, Marie A.D. Haverkort, Jas Khattra, Jessica N. McAlpine, Carien L. Creutzberg, Vincent T.H.B.M. Smit, C. Blake Gilks, Nanda Horeweg, Tjalling Bosse
Publikováno v:
JCO Global Oncology, Vol , Iss 9 (2023)
PURPOSEDetection of 11 pathogenic variants in the POLE gene in endometrial cancer (EC) is critically important to identify women with a good prognosis and reduce overtreatment. Currently, POLE status is determined by DNA sequencing, which can be expe
Externí odkaz:
https://doaj.org/article/fba14e34232b4bcea6998f7113f0afe7
Autor:
Nanda Horeweg, Hagma H. Workel, Dominik Loiero, David N. Church, Lisa Vermij, Alicia Léon-Castillo, Ricki T. Krog, Stephanie M. de Boer, Remi A. Nout, Melanie E. Powell, Linda R. Mileshkin, Helen MacKay, Alexandra Leary, Naveena Singh, Ina M. Jürgenliemk-Schulz, Vincent T. H. B. M. Smit, Carien L. Creutzberg, Viktor H. Koelzer, Hans W. Nijman, Tjalling Bosse, Marco de Bruyn, TransPORTEC consortium
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
Tertiary lymphoid structures (TLS) are associated with a reduced risk of cancer recurrence and improved response to immune checkpoint blockade in several tumor types. Here the authors identify L1CAM as a marker for mature TLS and show that the presen
Externí odkaz:
https://doaj.org/article/6cc5d5b840f843b2b959b31b5c279a0f
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Endometrial cancer (EC) diagnostics is evolving into a system in which molecular aspects are increasingly important. The traditional histological subtype-driven classification has shifted to a molecular-based classification that stratifies EC into DN
Externí odkaz:
https://doaj.org/article/1b018f63aa4f43d69bc08d0cb65b3b54
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Following the discovery of the four molecular subtypes of endometrial cancer (EC) by The Cancer Genome Atlas (TCGA) in 2013, subsequent studies used surrogate markers to develop and validate a clinically relevant EC classification tool to recapitulat
Externí odkaz:
https://doaj.org/article/f5db227f09784fa1bd8479417f9e80b1
Autor:
Kim E. Kortekaas, Saskia J. Santegoets, Ziena Abdulrahman, Vanessa J. van Ham, Marij van der Tol, Ilina Ehsan, Helena C. van Doorn, Tjalling Bosse, Mariëtte I. E. van Poelgeest, Sjoerd H. van der Burg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune infiltrate in the
Externí odkaz:
https://doaj.org/article/278594b3dd424428aaf79480406433b9
Autor:
Sarah Fremond, Sonali Andani, Jurriaan Barkey Wolf, Jouke Dijkstra, Sinéad Melsbach, Jan J Jobsen, Mariel Brinkhuis, Suzan Roothaan, Ina Jurgenliemk-Schulz, Ludy C H W Lutgens, Remi A Nout, Elzbieta M van der Steen-Banasik, Stephanie M de Boer, Melanie E Powell, Naveena Singh, Linda R Mileshkin, Helen J Mackay, Alexandra Leary, Hans W Nijman, Vincent T H B M Smit, Carien L Creutzberg, Nanda Horeweg, Viktor H Koelzer, Tjalling Bosse
Publikováno v:
The Lancet Digital Health, 5(2), e71-e82. Lancet Publishing Group
The Lancet Digital Health, 5(2), e71-e82. Elsevier
The Lancet Digital Health, 5(2), e71-e82. Elsevier Ltd.
The Lancet Digital Health, 5(2), e71-e82. Elsevier
The Lancet Digital Health, 5(2), e71-e82. Elsevier Ltd.
Background: Endometrial cancer can be molecularly classified into POLEmut, mismatch repair deficient (MMRd), p53 abnormal (p53abn), and no specific molecular profile (NSMP) subgroups. We aimed to develop an interpretable deep learning pipeline for wh